跳至主要内容
临床试验/NCT05933577
NCT05933577进行中(未招募)3 期

A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical Study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (INTerpath-001)

Merck Sharp & Dohme LLC165 个研究点 分布在 10 个国家目标入组 1,089 人开始时间: 2023年7月19日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
进行中(未招募)
入组人数
1,089
试验地点
165
主要终点
Recurrence-Free Survival (RFS)

研究概览

简要总结

The purpose of this study is to learn if intismeran autogene which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if intismeran autogene with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

盲法说明

Double blind

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The main inclusion criteria include but are not limited to the following:
  • Has surgically resected and histologically/pathologically confirmed diagnosis of Stage IIB or IIC, III, or IV cutaneous melanoma
  • Has not received any prior systemic therapy for their melanoma beyond surgical resection
  • No more than 13 weeks have passed between final surgical resection that rendered the participant disease-free and the first dose of pembrolizumab
  • Is disease free at the time of providing documented consent for the study
  • Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy (ART)

排除标准

  • The main exclusion criteria include but are not limited to the following:
  • Has ocular or mucosal melanoma
  • Has cancer that has spread to other parts of the body and cannot be removed with surgery
  • Has heart failure within the past 6 months
  • Has received prior cancer therapy or another cancer vaccine
  • Has another known cancer that that has spread to other parts of the body or has required treatment within the past 3 years
  • Has severe reaction to study medications or any of their substance used to prepare a drug
  • Have not recovered from major surgery or have ongoing surgical complications

研究组 & 干预措施

Intismeran autogene + Pembrolizumab

Experimental

Participants receive up to 9 doses of intismeran autogene via an intramuscular (IM) injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an intravenous (IV) infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.

干预措施: Intismeran autogene (Biological)

Intismeran autogene + Pembrolizumab

Experimental

Participants receive up to 9 doses of intismeran autogene via an intramuscular (IM) injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an intravenous (IV) infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.

干预措施: Pembrolizumab (Biological)

Placebo + Pembrolizumab

Active Comparator

Participants receive up to 9 doses of dose matched placebo to intismeran autogene via an IM injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an IV infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.

干预措施: Pembrolizumab (Biological)

Placebo + Pembrolizumab

Active Comparator

Participants receive up to 9 doses of dose matched placebo to intismeran autogene via an IM injection (every 3 weeks) plus up to 9 doses of pembrolizumab via an IV infusion (once every 6 weeks) until disease recurrence or unacceptable toxicity, or for a total treatment duration of up to approximately 56 weeks, whichever is sooner.

干预措施: Placebo (Other)

结局指标

主要结局

Recurrence-Free Survival (RFS)

时间窗: Up to approximately 74 months

RFS is defined as the length of time from when the participant starts the study until either the cancer comes back, or the cancer spreads as assessed by the investigator, or death due to any cause.

次要结局

  • Overall-Survival (OS)(Up to approximately 85 months)
  • Number of Participants Who Discontinue Study Treatment Due to an AE(Up to approximately 56 weeks)
  • Distant Metastasis-Free Survival (DMFS)(Up to approximately 85 months)
  • Number of Participants Who Experience an Adverse Event (AE)(Up to approximately 68 weeks)
  • Change from Baseline in the EORTC QLQ-C30 Physical Functioning (Items 1-5) Combined Score on the EORTC QLQ-C30(Baseline and up to approximately 85 months)
  • Change from Baseline in the EORTC QLQ-C30 Role Functioning (Items 6 and 7) Combined Score on the EORTC QLQ-C30(Baseline and up to approximately 85 months)
  • Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC)-Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status/Quality of Life (Items 29 and 30) Combined Score(Baseline and up to approximately 85 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (165)

Loading locations...

相似试验

相关资讯

Nanomedicine Strategies for Remodeling the Solid Tumor Microenvironment: Stromal Targeting, Hypoxia Modulation, and Photodynamic Immunotherapy- A comprehensive review in Frontiers in Oncology outlines how nanomedicine can remodel the solid tumor microenvironment through stromal targeting, hypoxia control, and photodynamic immune activation. - Cancer-associated fibroblasts, dense extracellular matrix, hypoxia, and immunosuppressive myeloid and lymphoid populations jointly limit drug delivery and treatment response in solid tumors. - The authors argue that biomarker-guided, mechanism-matched platforms with measurable microenvironmental endpoints—rather than ever-greater carrier complexity—offer the most realistic path to clinical translation. - Failed phase III trials such as HALO-301 and MAESTRO underscore that plausible stromal or hypoxia mechanisms do not guarantee survival benefit without validated spatial biomarkers and target-engagement measures.2 months agoPersonalized Cancer Vaccines Show Promise in Clinical Trials, Marking New Era in Immunotherapy- Breakthrough developments in genomic sequencing have enabled the identification of tumor-specific neoantigens, revolutionizing the approach to personalized cancer vaccine development. - The KEYNOTE-942 trial demonstrated significant improvement in relapse-free survival for melanoma patients receiving combination therapy of neoantigen vaccine mRNA-4157 with pembrolizumab compared to monotherapy. - Large-scale industry-funded trials are now underway across multiple cancer types, including melanoma, renal cell carcinoma, and pancreatic cancer, with some studies enrolling over 1,000 patients.last year